Status:
UNKNOWN
Effect tDCS of Motor Cortex on Chemotherapy Induced Peripheral Neuropathy
Lead Sponsor:
Assiut University
Conditions:
Chemotherapy-induced Peripheral Neuropathy
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and plati...
Detailed Description
Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and plati...
Eligibility Criteria
Inclusion
- any stage of cancer, with a confirmed treatment plan consisting of taxane-based or oxaliplatin-based chemotherapy, neuropathic pain and/or peripheral sensory neuropathy with VAS score ≥ 3 that are resistant to medical treatment
Exclusion
- patients with intracranial metallic devices or with pacemakers or any other device. - -W those with extensive myocardial ischemia,
- higher brain dysfunction,
- migraine headache,
- brain cancer or metastasis and
- those known to have epilepsy
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04833920
Start Date
April 1 2021
End Date
June 1 2022
Last Update
April 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
South Egypt Cancer Institute
Asyut, Egypt, 11715